D. Western Therapeutics Institute, Inc. provided consolidated earnings guidance for the full year ending December 31, 2024. For the full year, the company expected net sales of JPY 400 million, operating loss of JPY 1,400 million, loss attributable to owners of parent of JPY 1,390 million and loss per share of JPY 44.60.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
105 JPY | -1.87% | -4.55% | -25.53% |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-25.53% | 21.74M | |
+3.91% | 109B | |
+10.87% | 105B | |
+1.28% | 22.25B | |
-13.14% | 22.09B | |
-7.05% | 18.68B | |
-38.36% | 17.58B | |
-10.66% | 16.85B | |
+3.75% | 13.76B | |
+36.70% | 12.46B |
- Stock Market
- Equities
- 4576 Stock
- News D. Western Therapeutics Institute, Inc.
- D. Western Therapeutics Institute, Inc. Provides Consolidated Earnings Guidance for the Full Year Ending December 31, 2024